Economic Observation Network Eddie Pharmaceutical (688488) lowered the upper limit of its 2026 private placement fundraising on the evening of September 17, and there are still multiple uncertainties regarding related matters.

Private placement stocks:
On the evening of September 17th, the company lowered the upper limit of private placement fundraising for 2026 from 1.277 billion yuan to 945 million yuan, and made three key changes simultaneously 。

Recent company situation:
The core incremental drug ACC017 has just completed its Phase III enrollment and will only be declared for market in 2027. The production capacity for advanced expansion and depreciation of nearly ten million yuan per year need to be provisioned in advance; The contraction of overseas research and development prolongs the cycle of going global and weakens international competitiveness; Private placement still requires multiple approvals from the shareholders' meeting, Shanghai Stock Exchange, and China Securities Regulatory Commission, and there is uncertainty about whether and when it can be approved 。

The above content is based on publicly available information and does not constitute investment advice.